United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir and lamivudine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection. abacavir and lamivudine is contraindicated in patients: - who have the hla-b*5701 allele [see warnings and precautions (5.1)] . - with prior hypersensitivity reaction to abacavir [see warnings and precautions (5.1)] or lamivudine. - with moderate or severe hepatic impairment [see use in specific populations (8.7)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abacavir and lamivudine during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir or lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.76 mg (equivalent: abacavir, qty 600 mg) - tablet, film coated - excipient ingredients: sunset yellow fcf aluminium lake; magnesium stearate; microcrystalline cellulose; macrogol 8000; colloidal anhydrous silica; croscarmellose sodium; titanium dioxide; hypromellose - abacavir and lamivudine combination tablets are a combination of two nucleoside analogues (abacavir and lamivudine). ,abacavir and lamivudine combination tablets are indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir and lamivudine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection. abacavir and lamivudine is contraindicated in patients: - who have the hla-b*5701 allele [see warnings and precautions (5.1)] . - with prior hypersensitivity reaction to abacavir [see warnings and precautions (5.1)] or lamivudine. - with moderate or severe hepatic impairment [see use in specific populations (8.7)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abacavir and lamivudine during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir or lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.76 mg (equivalent: abacavir, qty 600 mg) - tablet, film coated - excipient ingredients: macrogol 8000; sunset yellow fcf aluminium lake; titanium dioxide; magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; hypromellose; microcrystalline cellulose - abacavir and lamivudine combination tablets are a combination of two nucleoside analogues (abacavir and lamivudine). ,abacavir and lamivudine combination tablets are indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.76 mg (equivalent: abacavir, qty 600 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; hypromellose; titanium dioxide; croscarmellose sodium; macrogol 8000; colloidal anhydrous silica; sunset yellow fcf aluminium lake; magnesium stearate - abacavir and lamivudine combination tablets are a combination of two nucleoside analogues (abacavir and lamivudine). ,abacavir and lamivudine combination tablets are indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - abacavir sulfate, quantity: 702 mg (equivalent: abacavir, qty 600 mg); lamivudine, quantity: 300 mg; dolutegravir, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; povidone; magnesium stearate; purified water; mannitol; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age who are antiretroviral treatment-na?ve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents (dolutegravir, abacavir or lamivudine) in triumeq.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - abacavir sulfate 702.78mg equivalent to abacavir 600 mg;  ; lamivudine 300mg - film coated tablet - active: abacavir sulfate 702.78mg equivalent to abacavir 600 mg   lamivudine 300mg excipient: colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry white 13b58894 purified talc silicified microcrystalline cellulose - antiretroviral combination therapy for the treatment of hiv in adults and adolescents from 12 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - lamivudine, quantity: 300 mg; abacavir hydrochloride monohydrate, quantity: 714.162 mg (equivalent: abacavir, qty 600 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; ferric oxide; titanium dioxide; hypromellose; sunset yellow fcf; polysorbate 80; macrogol 400 - abacavir/lamivudine lapl is a combination of two nucleoside analogues (abacavir and lamivudine). abacavir/lamivudine lapl is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - lamivudine, quantity: 300 mg; abacavir hydrochloride monohydrate, quantity: 714.162 mg (equivalent: abacavir, qty 600 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; ferric oxide; titanium dioxide; hypromellose; sunset yellow fcf; polysorbate 80; macrogol 400 - abacavir/lamivudine lapl is a combination of two nucleoside analogues (abacavir and lamivudine). abacavir/lamivudine lapl is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - lamivudine, quantity: 300 mg; abacavir hydrochloride monohydrate, quantity: 714.162 mg (equivalent: abacavir, qty 600 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; ferric oxide; titanium dioxide; hypromellose; sunset yellow fcf; polysorbate 80; macrogol 400 - abacavir/lamivudine lupin is a combination of two nucleoside analogues (abacavir and lamivudine). abacavir/lamivudine lupin is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.